Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS; Unconjugated
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab175475-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $239.90 | |
Ab175475-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,259.90 |
Purity≥95% (SDS-PAGE&SEC); Endotoxin Level≤1.0EU/mg; CHO; ELISA, FACS; Unconjugated
Product Name | Blinatumomab (anti-CD3&CD19) - Primary antibody, specific to CD3E; CD19, Human IgG1 |
---|---|
Synonyms | Blincyto,bscCD19xCD3;MEDI-538;MT-103;MT103 |
Specifications & Purity | Carrier Free, Recombinant, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC), Lot by Lot |
Specificity | CD3E; CD19 |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, Low Endotoxin, Moligand™, Recombinant, Validated |
Action Type | CROSS-LINKING AGENT |
Mechanism of action | Antibody of CD19;Antibody of CD3e |
Product Description | Blinatumomab (anti-CD3&CD19) is a bispecific monoclonal antibody which can specifically targets the CD19 antigen present on B cells. Blinatumomab (anti-CD3&CD19) can be used for the research of acute lymphoblastic leukemia. |
Light Chain Type | kappa |
---|---|
SDS-PAGE | 54.05 kDa |
Purification Method | Nickel affinity chromatography+Molecular sieve |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 853426-35-4 |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Wikipedia | Blinatumomab |
---|---|
IMGT/mAb-DB | 101 |
Enter Lot Number to search for COA:
1. Mølhøj M, Crommer S, Brischwein K, Rau D, Sriskandarajah M, Hoffmann P, Kufer P, Hofmeister R, Baeuerle PA. (2007) CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.. Mol Immunol, 44 (8): (1935-43). [PMID:17083975] |
2. Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P et al.. (2007) Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.. J Immunother, 30 (8): (798-807). [PMID:18049331] |
3. Aldoss I, Bargou RC, Nagorsen D, Friberg GR, Baeuerle PA, Forman SJ. (2017) Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.. Leukemia, 31 (4): (777-787). [PMID:28028314] |
4. Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA et al.. (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.. Blood, 131 (14): (1522-1531). [PMID:29358182] |
5. Slaney CY, Wang P, Darcy PK, Kershaw MH. (2018) CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.. Cancer Discov, 8 (8): (924-934). [PMID:30012854] |